Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trialResearch in context

Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trialResearch in context

Summary: Background: Although the antibody–drug conjugates (ADCs) have significantly improved the survival outcomes of patients with human epidermal receptor 2 (HER2)-expressing gastric or gastroesophageal junction (G/GEJ) cancer, the efficacy of ADC used as a single agent is limited. Therefore, it...

Full description

Bibliographic Details
Main Authors: Yakun Wang, Jifang Gong, Airong Wang, Jia Wei, Zhi Peng, Xicheng Wang, Jun Zhou, Changsong Qi, Dan Liu, Jian Li, Ming Lu, Zhihao Lu, Yanshuo Cao, Jiajia Yuan, Ruyan Zhang, Jianmin Fang, Xiaotian Zhang, Lin Shen
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:EClinicalMedicine
Subjects:
Her2
ADC
PD-1
Gastric cancer
Solid tumours
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023005928

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023005928

Similar Items